NAFLD was characterized by the disorder of the expression of a series of lipid metabolic genes, including the increase of DGAT, FAT/CD36, SREBP-1c, ACC, FAS and the decrease of PPAR-α, CPT-1 [26], [27]. This evidence concerns the gene FAS and metabolic dysfunction-associated steatotic liver disease.